Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.91 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 7× Globus Medical Inc. Class A Common Stock's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| GMED | VCIT | |
|---|---|---|
Market Cap | $10.25B | $72.20B |
Volume | 1,059,528 | 13,245,117 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $84.82 |
52-Week Low | $58.33 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $78.48, down 0.03% on the day. The technical outlook is mixed with a bullish overall signal but bearish moving averages, while fundamentals are supported by a 4.8% yield and low 0.03% expense ratio. Recent news highlights institutional buying and favorable comparisons to peer bond ETFs.
The outlook for VCIT is positive for income-focused investors seeking corporate bond exposure with low costs. Key opportunities include attractive yield and institutional interest, while risks involve interest rate sensitivity and credit spread volatility in the corporate bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
